HOXB13 and prostate adenocarcinoma: HOXB13 was found to be a pioneer factor, with itsbinding sites often overlapping with those of FOXA1, GATA2and other DNA-binding proteins in cell lines originating fromprostate tissue (Hankey et al., 2020; Pomerantz et al., 2020).HOXB13 expression levels are elevated in approximately 85 %of prostate adenocarcinoma cases, and this correlates withresistance to AR-targeted therapy, as well as with metastasisand tumor recurrence during treatment (Zabalza et al., 2015;Yao et al., 2019; Weiner et al., 2021).